MX2022015959A - Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. - Google Patents

Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.

Info

Publication number
MX2022015959A
MX2022015959A MX2022015959A MX2022015959A MX2022015959A MX 2022015959 A MX2022015959 A MX 2022015959A MX 2022015959 A MX2022015959 A MX 2022015959A MX 2022015959 A MX2022015959 A MX 2022015959A MX 2022015959 A MX2022015959 A MX 2022015959A
Authority
MX
Mexico
Prior art keywords
fxi
antigen
binding fragment
fxia antibody
pharmaceutical use
Prior art date
Application number
MX2022015959A
Other languages
English (en)
Inventor
Jin Zhang
Xiao Liu
Lei Wang
Changyong Yang
Yang Yang
Ran Wu
Xugang He
Dongmei Hu
Yanping Du
Chenxi Shen
Original Assignee
Beijing Tuo Jie Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tuo Jie Biopharmaceutical Co Ltd filed Critical Beijing Tuo Jie Biopharmaceutical Co Ltd
Publication of MX2022015959A publication Critical patent/MX2022015959A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Se proporciona un anticuerpo anti-FXI/FXIa, un fragmento del mismo que se une al antígeno y un uso farmacéutico del mismo, así como una composición farmacéutica que comprende el anticuerpo anti-FXI/FXIa o el fragmento del mismo que se une al antígeno, y un método para tratar y prevenir una enfermedad, en particular un método para tratar la trombosis o enfermedades o trastornos relacionados con el tromboembolismo.
MX2022015959A 2020-07-02 2021-07-02 Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. MX2022015959A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010633951 2020-07-02
PCT/CN2021/104253 WO2022002249A1 (zh) 2020-07-02 2021-07-02 抗FXI/FXIa抗体、其抗原结合片段及医药用途

Publications (1)

Publication Number Publication Date
MX2022015959A true MX2022015959A (es) 2023-01-24

Family

ID=79317479

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015959A MX2022015959A (es) 2020-07-02 2021-07-02 Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.

Country Status (11)

Country Link
US (1) US20230220111A1 (es)
EP (1) EP4177274A4 (es)
JP (1) JP2023532251A (es)
KR (1) KR20230034361A (es)
CN (3) CN117487016A (es)
AU (1) AU2021302202A1 (es)
BR (1) BR112022026533A2 (es)
CA (1) CA3184718A1 (es)
MX (1) MX2022015959A (es)
TW (1) TW202214701A (es)
WO (1) WO2022002249A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202333789A (zh) * 2022-01-05 2023-09-01 大陸商上海邁晉生物醫藥科技有限公司 一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PL1644412T5 (pl) 2003-07-01 2019-01-31 Ucb Biopharma Sprl Modyfikowane fragmenty Fab przeciwciała
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
ES2622460T3 (es) 2007-09-26 2017-07-06 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
DK2373691T3 (en) * 2008-12-18 2019-04-15 Oregon Health&Science Univ ANTI-FXI ANTIBODIES AND PROCEDURES FOR USE
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
DK2847228T3 (en) * 2012-05-10 2018-11-19 Bayer Pharma AG ANTIBODIES THAT CAN BIND TO COAGULATION FACTOR XI AND / OR ITS ACTIVATED FORM FACTOR XIA, AND APPLICATIONS THEREOF
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US10913802B2 (en) * 2015-07-21 2021-02-09 Dyax Corp. Monoclonal antibody inhibitor of factor XIIA
WO2017015619A1 (en) * 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
EP3433279A1 (en) * 2016-03-23 2019-01-30 Prothix BV Monoclonal antibodies against the active site of factor xi and uses thereof
GB201609742D0 (en) * 2016-06-03 2016-07-20 Medical Res Council Technology Improvements relating to antibodies
KR102218714B1 (ko) * 2016-06-14 2021-02-24 머크 샤프 앤드 돔 코포레이션 항응고 인자 xi 항체
CA3037087A1 (en) * 2016-09-20 2018-03-29 Bayer Pharma Aktiengesellschaft Antibodies against factor xi and uses thereof
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用

Also Published As

Publication number Publication date
US20230220111A1 (en) 2023-07-13
TW202214701A (zh) 2022-04-16
JP2023532251A (ja) 2023-07-27
WO2022002249A1 (zh) 2022-01-06
KR20230034361A (ko) 2023-03-09
AU2021302202A1 (en) 2023-02-16
CN114269790A (zh) 2022-04-01
CN117487016A (zh) 2024-02-02
EP4177274A4 (en) 2024-04-03
BR112022026533A2 (pt) 2023-01-17
EP4177274A1 (en) 2023-05-10
CN114269790B (zh) 2023-11-24
CN117487017A (zh) 2024-02-02
CA3184718A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
PE20210167A1 (es) Proteinas de union multiespecificas y mejoras con estas
NO20055415L (no) Humaniserte antistoffer som gjenkjenner beta-amyloidpeptid
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
JO2576B1 (en) Antibodies
AU2019206958A1 (en) PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
MX2019009500A (es) Anticuerpos anti factor de coagulación xi.
EA201891388A1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
BR112022003956A2 (pt) Anticorpos anti-cd73
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
BR112021014699A2 (pt) Métodos de tratamento de mieloma múltiplo
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2023002805A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos.
MX2021004351A (es) Metodo para el tratamiento de miastenia grave.
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
ZA202200906B (en) Anti-her2/anti-4-1bb bispecific antibody and use thereof
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.
AR095499A1 (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b
MX2022015959A (es) Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
ZA202200905B (en) Anti-egfr/anti-4-1bb bispecific antibody and use thereof
WO2019224385A3 (en) Combined bispecific antibody and immuno-oncology therapies
PH12017502126A1 (en) Novel anti-human ngf antibody fab fragment
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina